Engineering novel proteins through directed evolution have become a foundation of protein engineering in biotech. However, these techniques are incapable of simultaneous engineering of protein-protein pairs through library-on-library selections.
Stanford researchers have engineered retroviral and virus-like delivery systems for producing universal pseudotyped vehicles for cell and gene therapies.
Researchers at Stanford have developed a method of culture media supplementation with inosine during the chimeric antigen receptor (CAR)-T cell manufacturing process which can alter and enhance CAR-T cell metabolism and anti-tumor functions.